Printer Friendly

GENEVA PHARMACEUTICALS AND UPJOHN ANNOUNCE AGREEMENT

 BROOMFIELD, Colo./KALAMAZOO, Mich., Jan. 19 /PRNewswire/ -- Geneva Pharmaceuticals, Inc., and The Upjohn Company (NYSE: UPJ) announced today that Geneva will market generic versions of Upjohn's branded Xanax (alprazolam) and Halcion (triazolam) at a later date.
 The two companies had earlier announced an agreement whereby Geneva would market generic versions of unspecified Upjohn products.
 "This agreement is part of Upjohn's overall strategic plan to take advantage of opportunities in selected generic markets around the world," said Jack J. Jackson, Senior Vice President for Western Hemisphere Pharmaceutical Operations.
 Geneva Pharmaceuticals, a subsidiary of the CIBA-GEIGY Corporation, is a leading developer, manufacturer and marketer of high-quality generic pharmaceutical products. The company is headquartered in Broomfield, with distribution capabilities throughout the United States.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, Mich., the company has been dedicated to improving health and nutrition for more than a century.
 -0- 1/19/93
 /CONTACT: John P. Lambrechts of The Upjohn Company, 616-323-7076/
 (UPJ)


CO: The Upjohn Company; Geneva Pharmaceuticals, Inc. ST: Michigan, Colorado IN: MTC SU: CON

ML -- DE004 -- 6158 01/19/93 09:03 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 19, 1993
Words:199
Previous Article:KELLOGG COMPANY SALES UP 7 PERCENT FROM 1991
Next Article:KMART CORPORATION BOARD DECLARES DIVIDENDS
Topics:


Related Articles
UPJOHN CONSUMER PRODUCTS DIVISION ENTERS INTO MARKETING AGREEMENT WITH MCNEIL CONSUMER PRODUCTS COMPANY
GENEVA PHARMACEUTICALS AND UPJOHN EXTEND AGREEMENT
,sandi,michi r f bc-Gensia-Upjohn-allianc
UPJOHN TO DEVELOP ANTI-CANCER AGENT FROM JAPAN
SMITHKLINE BEECHAM INTRODUCES NEW FORMULATION OF DYAZIDE; ALSO ANNOUNCES DISTRIBUTION AGREEMENT WITH GENEVA PHARMACEUTICALS
MGI PHARMA GRANTS CANADIAN RIGHTS FOR SALAGEN(R) TABLETS TO UPJOHN CANADA
INCYTE AND UPJOHN SIGN $20 MILLION DATABASE ACCESS AGREEMENT
UPJOHN AND GENSIA RESTRUCTURE MULTISOURCE ONCOLYTIC DRUG ALLIANCE
UPJOHN BOARD APPROVES RESTRUCTURED GENSIA AGREEMENT FOR MULTISOURCE ONCOLYTIC DRUG ALLIANCE
Incyte and Pharmacia & Upjohn Extend and Expand Genomic Database Partnership

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters